The Select MDX is a highly predictive urine test to help identify men at risk for aggressive prostate cancer prior to initial biopsy. If you have an elevated PSA level, it is important to understand your risk for aggressive, potentially lethal, prostate cancer. Select mdx can provide you and your urologist with better insight on your personal prostate cancer risk and whether you should have an initial prostate biopsy.

It’s Non-Invasive and Convenient

• All you need to do is provide a urine specimen during a visit to your urologist’s office.
• The specimen will be sent to Mdxhealth for Select MDX for Prostate Cancer testing.
• Your Select MDX test results will be sent to your urologist within 5 days.
• The Select MDX test measures the amount of two genes associated with aggressive
  prostate cancer. The measurement of these prostate cancer-specific genes in combination with traditional clinical risk factors—such as your age, PSA (prostate-specific antigen) level, prostate volume, family history of prostate cancer, and the outcome of a digital rectal examination (DRE) results in your Select MDX personalized risk score.
• Your Select MDX risk score gives you and your physician better insight on whether or not prostate cancer is likely to be found upon initial biopsy. Knowing your Select MDX risk score, you and your physician can make an informed decision if you may benefit from a prostate biopsy that could detect cancer at an early stage so you can receive appropriate treatment sooner. The Select MDX test is included in the 2020 National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection.